TBT DESK: In a promising step towards advancing pharmaceutical research and nurturing the next generation of scientists, Beximco Pharmaceuticals Limited has signed a Memorandum of Understanding (MoU) with North South University (NSU), one of Bangladesh's leading academic institutions.
The agreement, signed on Monday, 5 May, marks a collaborative effort between Beximco Pharma and NSU's Department of Pharmaceutical Sciences, aimed at enhancing research, innovation, and career development opportunities for pharmacy students.
Under the terms of the MoU, Beximco Pharma will extend financial support and access to its state-of-the-art research facilities to select Master of Pharmacy (MPharm) students from NSU. These students will benefit from hands-on experience and resources as they pursue thesis work on cutting-edge pharmaceutical topics.
Speaking on the occasion, Rabbur Reza, Chief Operating Officer of Beximco Pharmaceuticals, emphasised the importance of industry-academia collaboration. "This partnership with North South University marks an important step in bridging the gap between industry and academia. At Beximco Pharma, being a socially responsible entity, we recognise the immense potential of such collaboration in accelerating scientific research to meet the needs of our patients. This will also help us build new capabilities to move up the pharmaceutical value chain," he said.
Professor Abdul Hannan Chowdhury, Vice Chancellor of NSU, echoed this sentiment: "We are deeply committed to fostering academic excellence through meaningful partnerships with industry. We believe this collaboration will bring together the best talents and help create an ecosystem of innovation in the country."
This initiative highlights Beximco Pharma's continued investment in research and its role as a key player in Bangladesh's healthcare and pharmaceutical sectors. The company, which began its journey in 1976, now operates in over 60 countries and remains the only Bangladeshi firm listed on the London Stock Exchange's AIM market.
With a global reputation for quality and innovation, Beximco Pharma has received numerous accolades, including recognition in Forbes Asia's Best Under a Billion 2023 and multiple international pharmaceutical awards. The company currently employs over 5,900 people and offers more than 500 products worldwide.
This MoU is expected to inspire future collaborations and foster a culture of shared innovation between academia and industry-paving the way for transformative solutions in healthcare.